Tonix Pharmaceuticals Holding Corp. reported second quarter 2026 operating results, announcing net product revenue of approximately $13.5 million, a significant increase from $2.0 million in the prior year period. Net sales of its flagship fibromyalgia treatment TONMYA totaled approximately $11 million, reflecting a 197% quarter-over-quarter growth driven by expanded payer coverage reaching 136 million covered lives and prescription volume doubling to 12,592 units. The company reported a net loss of $40.6 million, or $2.44 per share, compared to a $28.3 million loss in the same period last year, as R&D and SG&A expenses rose due to commercial launch investments and clinical trial costs. Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents.
